MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer.
Zinab O DohaXiaoyan WangNicholas L CalistriJennifer EngColin J DanielLuke TernesEun Na KimCarl PelzMichael MunksCourtney BettsSunjong KwonElmar BucherXi LiTrent WaughZuzana TatarovaDylan BlumbergAaron KoNell KirchbergerJennifer A PietenpolMelinda E SandersEllen M LangerMu-Shui DaiGordon B MillsKoei ChinYoung Hwan ChangLisa M CoussensJoe W GrayLaura M HeiserRosalie C SearsPublished in: Nature communications (2023)
Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.
Keyphrases
- single cell
- mouse model
- poor prognosis
- endothelial cells
- transcription factor
- rna seq
- induced pluripotent stem cells
- end stage renal disease
- cell proliferation
- high throughput
- chronic kidney disease
- pluripotent stem cells
- high resolution
- emergency department
- bone marrow
- ejection fraction
- gene expression
- prognostic factors
- case report
- dna methylation
- genome wide
- single molecule
- mass spectrometry
- copy number
- nucleic acid
- label free
- free survival
- adverse drug